Danaher Corporation Q1 2026 Earnings Recap

Danaher delivered a solid start to 2026 with modest core revenue growth driven by strength in bioprocessing and Life Sciences, amid a lighter respiratory season; adjusted EPS rose nearly 10%, supported by operational efficiencies and strategic M&A activity.

Key Takeaways

• Core revenue increased 0.5% YoY, with a 3% growth in non-respiratory segments offsetting a 2.5% decline in respiratory revenue.
• Adjusted EPS grew 9.5% to $2.06, aided by cost savings and robust free cash flow generation of $1.1 billion.
• Strategic M&A progress includes the pending Masimo acquisition, expected to be accretive within the first year and deliver high single-digit Returns by Year 5.
• Growth in China accelerated, with Life Sciences and Biotechnology outperforming expectations despite continued headwinds in Diagnostics.
• Operational focus remains on leveraging DBS to enhance innovation, margins, and customer value, with new product launches reinforcing competitive positioning.